Testosterone Testing: What Labs Should Consider In 2026
Quantitative testosterone testing sits at the intersection of reproductive endocrinology, urology, and metabolic health. Because testosterone functions as an androgen marker for gonadal and adrenal androgen status in both female and male patients, laboratories cannot treat it as a stand-alone number. Accurate interpretation depends on understanding the clinical scenario behind the request, the direction of change relative to reference values, and the companion markers needed to confirm a diagnosis. The Sex Hormones Clinical Knowledge Graph developed by Poclight organizes testosterone alongside eight other analytes—β-hCG, LH, FSH, AMH, Cortisol, Progesterone, E2, and Prolactin—to support this kind of multi-tier endocrine pathway assessment, separating central (brain and pituitary) dysfunction from peripheral (adrenal and gonadal) dysfunction.
Why Quantitative Testosterone Testing Matters
Testosterone assessment is requested across a wide range of presentations: polycystic ovary syndrome, adrenal tumors, congenital adrenal hyperplasia (CAH), testicular tumors, steroid abuse, hypothalamic amenorrhea, hypogonadism, and aging-related androgen decline. Because the same analyte can signal androgen excess in one population and androgen deficiency in another, laboratories need to document patient sex, clinical indication, and sample timing before releasing a result for interpretation. This is consistent with Bhasin, S., et al. (2018), Testosterone therapy in men with hypogonadism, Journal of Clinical Endocrinology & Metabolism, 103(5), 1715–1744, which underscores that testosterone values must always be read against the specific clinical question being asked.
Elevation Patterns Laboratories Should Flag
In female patients, elevated testosterone is associated with PCOS, adrenal tumors, and CAH. In male patients, elevation is associated with testicular tumors and steroid abuse. Laboratories should recognize that an isolated elevated result does not distinguish between these conditions; it signals the need for additional endocrine or imaging workup rather than a final diagnosis. For PCOS specifically, the disease/disorder interpretation data show testosterone trending upward (↑), while progesterone is decreased (↓), confirming anovulation. This pattern aligns with the Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group (2004) revised 2003 consensus on diagnostic criteria, published in Fertility and Sterility, 81(1), 19–25, which laboratories and clinicians continue to reference when evaluating androgen excess in women.
Decrease Patterns Laboratories Should Flag
In female patients, decreased testosterone is linked to hypothalamic amenorrhea. In male patients, it is linked to hypogonadism and aging. Within the broader disease/disorder interpretation framework, testosterone is markedly decreased (↓↓) in Primary Testicular Failure and Klinefelter Syndrome, decreased (↓) in Hypogonadotropic Hypogonadism in both sexes, decreased (↓) in males with Hyperprolactinemia, and decreased (↓) in males with Adrenal Insufficiency. By contrast, testosterone is increased (↑) in females with Cushing's Syndrome and markedly increased (↑↑) in both sexes with Congenital Adrenal Hyperplasia. These directional patterns show why a single testosterone value, read in isolation, cannot differentiate between primary gonadal failure, central hypothalamic-pituitary dysfunction, and adrenal pathology.
Confirmatory Testing and Diagnostic Thresholds
Laboratories should be prepared to support confirmatory workflows rather than relying on testosterone alone. For Klinefelter Syndrome, the clinical interpretation note specifies that FSH and LH are markedly elevated (↑↑) together with decreased testosterone, and that karyotype 47,XXY is confirmatory. For Primary Testicular Failure, the note specifies that results should be confirmed with testicular ultrasound. This means a quantitative testosterone result flagged as low in a male patient should prompt consideration of paired gonadotropin testing (LH and FSH) and, where indicated, karyotyping or imaging, rather than being interpreted as a standalone finding.
Adrenal-related causes of altered testosterone also require corroborating evidence. Congenital Adrenal Hyperplasia is characterized by markedly elevated 17-OH Progesterone, with a diagnostic threshold greater than 10 ng/mL, occurring alongside increased testosterone in both sexes. Adrenal Insufficiency, which is associated with decreased testosterone in males, is also characterized by markedly decreased cortisol, with an AM cortisol below 3 μg/dL considered diagnostic. These relationships are consistent with Husebye, E. S., Pearce, S. H., Krone, N. P., & Kämpe, O. (2021), Adrenal insufficiency, published in The Lancet, 397(10274), 613–629, and with Øksnes, M., & Husebye, E. S. (2023), Approach to the Patient: Diagnosis of Primary Adrenal Insufficiency in Adults, published in The Journal of Clinical Endocrinology & Metabolism, 109(1), 269–278. Laboratories evaluating low testosterone in a male patient should therefore consider whether adrenal function markers are also warranted.
Testosterone Within a Broader Endocrine Panel
Because testosterone sits alongside gonadotropins, adrenal markers, and reproductive hormones within the same clinical pathway, Poclight's 9-analyte sex hormone profile is structured to support clinical evaluation of reproductive development, fertility, libido, bone health, metabolic balance, menstrual regulation, and spermatogenesis. For example, pairing testosterone with LH and FSH supports distinction between primary gonadal failure and central hypothalamic/pituitary causes, since LH and FSH are markedly elevated in Primary Testicular Failure and Klinefelter Syndrome but markedly decreased in Hypogonadotropic Hypogonadism—patterns that mirror the direction of testosterone change in each condition. Similarly, pairing testosterone with cortisol and progesterone supports evaluation of adrenal contributions, such as CAH and Adrenal Insufficiency, where testosterone, cortisol, and 17-OH Progesterone move in characteristic, documented directions.
Delivery and Reporting Considerations
Testosterone testing is delivered as clinical laboratory testing, and interpretation should follow local laboratory standards or guidelines. Laboratories serving reproductive endocrinology, urology, endocrinology, and metabolic health settings should ensure that result reports communicate not just the numeric value but the directional context—elevation or decrease—relative to the suspected clinical condition. Given that the same analyte can point toward androgen excess disorders such as PCOS and CAH, or androgen deficiency disorders such as hypogonadism and Klinefelter Syndrome, clear reporting practices and access to paired analytes within a single endocrine panel reduce the risk of misinterpretation.
In summary, laboratories performing quantitative testosterone testing should consider patient sex and clinical indication, the direction of change relative to the suspected disorder, the need for confirmatory markers such as LH, FSH, karyotype, or imaging, and the value of interpreting testosterone within a multi-analyte framework rather than in isolation. Poclight's Sex Hormones Clinical Knowledge Graph reflects this approach by organizing testosterone alongside β-hCG, LH, FSH, AMH, Cortisol, Progesterone, E2, and Prolactin to support differentiated, evidence-referenced interpretation across reproductive, developmental, metabolic, and adrenal conditions.
www.poclight.com
Nanjing Poclight Biotechnology Co., Ltd
About Author
